Physician profile
Dale E Ekstrum
NPI 1225106602
$2,470.26
in general payments reported to CMS, 2019-2025
21 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $505 · 2021: $265 · 2022: $285 · 2023: $347 · 2024: $194 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $766.79 | 2019-2025 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $291.08 | 2019-2025 | Breztri, Farxiga |
| Pfizer INC. | $256.99 | 2019-2022 | |
| Allergan, INC. | $227.17 | 2019-2022 | |
| Abbvie INC. | $170.90 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $148.95 | 2019-2022 | |
| Novo Nordisk INC | $80.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $72.93 | 2019-2021 | |
| Amarin Pharma, INC. | $61.45 | 2019-2020 | |
| Genentech USA, INC. | $56.62 | 2020 | |
| Bioventus LLC | $56.45 | 2019-2021 | |
| Revance Therapeutics, INC. | $52.05 | 2024 | Daxxify |
| Takeda Pharmaceuticals U.S.A., INC. | $47.43 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $34.98 | 2023 | |
| Lilly USA, LLC | $28.81 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.12 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $20.68 | 2022 | |
| Gilead Sciences, INC. | $20.17 | 2020 | |
| Coloplast Corp | $17.72 | 2023 | Altis |
| Sanofi Pasteur INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Ekstrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.